Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and
paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or
die. Combining more than one drug and giving them after surgery may kill any remaining tumor
cells. It is not yet known which combination chemotherapy regimen is more effective in
treating resected breast cancer.
PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination
chemotherapy to see how well they work in treating patients who have undergone surgery for
stage I, stage II, or stage III breast cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.